Mosaic ImmunoEngineering (CPMV) Convertible Debt (2021 - 2026)
Mosaic ImmunoEngineering (CPMV) posted quarterly Convertible Debt of $1.5 million for Q1 2026, up 5.2% year-over-year from $1.4 million in Q1 2025, and up 1.23% quarter-over-quarter from $1.5 million in Q4 2025.
Mosaic ImmunoEngineering (CPMV) Convertible Debt (2021 - 2026) Analysis & Trends
Mosaic ImmunoEngineering's Convertible Debt history runs 6 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- In Q1 2026, Convertible Debt rose 5.2% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (up 5.2% YoY), while the FY2025 annual figure was $1.5 million, up 5.27% from the prior year.
- Convertible Debt for Q1 2026 stood at $1.5 million, up from $1.5 million in the prior quarter.
- The five-year high for Convertible Debt was $1.5 million in Q1 2026, with the low at $1.1 million in Q1 2022.
- The 5-year median for Convertible Debt is $1.3 million (2024), against an average of $1.3 million.
- The sharpest annual moves came in 2022 and 2026: Convertible Debt jumped 85.58% in 2022, then rose 5.2% in 2026.
- Mosaic ImmunoEngineering's Convertible Debt stood at $1.2 million in 2022, then rose by 7.26% to $1.3 million in 2023, then increased by 5.69% to $1.4 million in 2024, then climbed by 5.27% to $1.5 million in 2025, then rose by 1.23% to $1.5 million in 2026.
- Business Quant data shows CPMV's Convertible Debt at $1.5 million in Q1 2026, $1.5 million in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | Mosaic ImmunoEngineering | 3.68 Mn | 3.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.48 Mn |
| Dec 31, 2025 | 1.47 Mn |
| Sep 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | 1.43 Mn |
| Mar 31, 2025 | 1.41 Mn |
| Dec 31, 2024 | 1.39 Mn |
| Sep 30, 2024 | 1.37 Mn |
| Jun 30, 2024 | 1.36 Mn |
| Mar 31, 2024 | 1.34 Mn |
| Dec 31, 2023 | 1.32 Mn |
| Sep 30, 2023 | 1.30 Mn |
| Jun 30, 2023 | 1.28 Mn |
| Mar 31, 2023 | 1.26 Mn |
| Dec 31, 2022 | 1.23 Mn |
| Sep 30, 2022 | 1.19 Mn |
| Jun 30, 2022 | 1.16 Mn |
| Mar 31, 2022 | 1.11 Mn |
| Dec 31, 2021 | 735,148.00 |
| Sep 30, 2021 | 709,831.00 |
| Jun 30, 2021 | 622,933.00 |